18.02
-0.29 (-1.58%)
| Previous Close | 18.31 |
| Open | 18.24 |
| Volume | 614,011 |
| Avg. Volume (3M) | 1,226,831 |
| Market Cap | 1,616,393,984 |
| Price / Earnings (Forward) | 312.50 |
| Price / Sales | 0.550 |
| Price / Book | 1.10 |
| 52 Weeks Range | |
| Earnings Date | 10 Mar 2025 - 14 Mar 2025 |
| Profit Margin | -10.08% |
| Operating Margin (TTM) | -1.36% |
| Diluted EPS (TTM) | -2.44 |
| Quarterly Revenue Growth (YOY) | -5.50% |
| Total Debt/Equity (MRQ) | 79.74% |
| Current Ratio (MRQ) | 1.18 |
| Operating Cash Flow (TTM) | 263.10 M |
| Levered Free Cash Flow (TTM) | 368.20 M |
| Return on Assets (TTM) | -1.04% |
| Return on Equity (TTM) | -13.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Fortrea Holdings Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.60 |
|
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.28% |
| % Held by Institutions | 112.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Barclays, 38.74%) | Hold |
| 25.00 (Baird, 38.74%) | Hold | |
| 25.00 (TD Cowen, 38.74%) | Hold | |
| Median | 25.00 (38.74%) | |
| Low | 23.00 (Citigroup, 27.64%) | Hold |
| Average | 24.50 (35.96%) | |
| Total | 4 Hold | |
| Avg. Price @ Call | 21.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Dec 2024 | 23.00 (27.64%) | Hold | 19.45 |
| Baird | 06 Dec 2024 | 25.00 (38.73%) | Hold | 21.67 |
| 11 Nov 2024 | 30.00 (66.48%) | Buy | 22.75 | |
| Barclays | 11 Nov 2024 | 25.00 (38.73%) | Hold | 22.75 |
| TD Cowen | 11 Nov 2024 | 25.00 (38.73%) | Hold | 22.75 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PIKE THOMAS | - | 18.31 | -11,268 | -206,317 |
| Aggregate Net Quantity | -11,268 | |||
| Aggregate Net Value ($) | -206,317 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 18.31 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PIKE THOMAS | Officer | 13 Jan 2025 | Sell (-) | 11,268 | 18.31 | 206,317 |
| Date | Type | Details |
|---|---|---|
| 26 Nov 2024 | Announcement | Fortrea to Present at the Citi Global Healthcare Conference |
| 26 Nov 2024 | Announcement | Fortrea to Present at the Evercore HealthCONx Conference |
| 08 Nov 2024 | Announcement | Fortrea Reports Third Quarter 2024 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |